Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Cancer
Tapan KadiaFarhad Ravandi

Abstract

Activating mutations in RAS are frequently present in patients with acute myeloid leukemia (AML), but their overall prognostic impact is not clear. A retrospective analysis was performed to establish the clinical characteristics of patients with RAS-mutated (RAS(mut) ) AML, to analyze their outcome by therapy, and to describe the proteomic profile of RAS(mut) compared with wild-type RAS (RAS(WT) ) AML. Of 609 patients with newly diagnosed AML, 11% had RAS(mut) . Compared with RAS(WT) , patients with RAS(mut) AML were younger (median age, 54 years vs 63 years; P = .001), had a higher white blood cell count (16K mm(-3) vs 4K mm(-3) ; P < 0.001) and bone marrow blast percentage (56% vs 42%; P = .01) at diagnosis, and were less likely to have an antecedent hematologic disorder (36% vs 50%; P = .03). The inv(16) karyotype was overrepresented in patients with RAS(mut) and the -5 and/or -7 karyotype was underrepresented. RAS mutations were found to have no prognostic impact on overall survival or disease-free survival overall or within cytogenetic subgroups. There was a suggestion that patients with RAS(mut) benefited from cytarabine (AraC)-based therapy. Proteomic analysis revealed simultaneous upregulation of the RAS-Raf-MAP kinase ...Continue Reading

References

Mar 1, 1989·Japanese Journal of Cancer Research : Gann·H TsudaM Terada
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J W JanssenC R Bartram
Dec 1, 1996·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·B HunyadyE Mezey
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M Beaupre, R Kurzrock
Jan 2, 2003·Nature Reviews. Cancer·Julian Downward
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas IllmerMarkus Schaich
Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Jun 30, 2007·Bioinformatics·Jianhua HuGordon B Mills
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas NeubauerClara D Bloomfield
Aug 12, 2008·Seminars in Oncology·Claudia SchollStefan Fröhling
Oct 9, 2008·Blood·Steven M KornblauGordon B Mills
Apr 2, 2009·Bioinformatics·E Shannon NeeleyKeith A Baggerly
Jul 29, 2009·Nature Reviews. Clinical Oncology·Nicola NormannoFortunato Ciardiello
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick J RobertsMark A Socinski

❮ Previous
Next ❯

Citations

Dec 18, 2013·Apoptosis : an International Journal on Programmed Cell Death·P Y MakB Z Carter
Feb 10, 2016·Cancer Cell·Najoua LalaouiJohn Silke
Mar 30, 2016·Molecular Neurobiology·Chunling JiangOuping Huang
Jun 13, 2013·Expert Opinion on Therapeutic Targets·Camilla EvangelistiAlberto M Martelli
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Tapan M KadiaHagop M Kantarjian
Mar 31, 2015·Nature Genetics·Zhen ZhaoScott W Lowe
Jul 7, 2017·Small GTPases·Emily J Pomeroy, Craig E Eckfeldt
Mar 26, 2019·Current Medicinal Chemistry·Nessar Ahmad AzrakhshAstrid Olsnes Kittang
Oct 24, 2019·Cancer Biomarkers : Section a of Disease Markers·Xinpei ZhangLin Fu
Oct 28, 2019·Oncotarget·Amanda M SmithAndrew S Moore
Jul 6, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Anuradha KirtoniaManoj Garg
Jul 3, 2021·Cancers·Nam H K NguyenJatinder K Lamba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.